Work

Fixed duration subcutaneous (SC) mosunetuzumab (Mosun) in patients with previously untreated high-tumor burden follicular lymphoma (FL): Interim results from the phase II MorningSun study.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.7014

Authors: Ian W. Flinn, John M. Burke, Jeff Porter Sharman, Bertrand Marquess Anz, Richard Zuniga, Aung M. Tun, Prachi Jani, Juliana M.L. Biondo, Mei Wu, Yong Mun, Vivek S. Chopra, Rona Farighi, Tony Lin, Jose Caetano Villasboas, Lihua Elizabeth Budde

Institutions: Tennessee Oncology, Rocky Mountain Cancer Centers, Willamette Valley Cancer Institute and Research Center, The University of Kansas Cancer Center, Genentech, Mayo Clinic, City Of Hope National Medical Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Genentech

OpenAlex ID: W4410818000

Cites:

Cited by: 1

Related to: 10